Tirzepatide
Tirzepatide from the Nexus GLP-1 & Metabolic catalog, supplied for controlled in-vitro research workflows.
Ships from the US with tracking.
Catalog active: Catalog pricing is active. Live warehouse counts are not published.
- Lot-specific COA
- HPLC + MS fields
- Batch archived
For in-vitro research use only. Not for human consumption.
Tirzepatide is a first-in-class dual incretin receptor agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism of action allows researchers to study the synergistic effects of two key metabolic hormone pathways.
No sequence is listed in the current catalog record for this product.
- CAS
- 2023788-19-2
- MW
- 4813.45 g/mol
- Sequence
- Not listed
- Half-life
- Not listed
- Formula
- C225H348N48O68
- Purity
- 99.55%
- Form
- Lyophilized powder
- Class
- Dual GIP/GLP-1 Receptor Agonist
The dossier.
Compound Overview
Tirzepatide is a first-in-class dual incretin receptor agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. By engaging both pathways, it gives researchers a way to examine the combined signaling behavior of two major metabolic hormone systems in controlled laboratory studies.
Research Background & Published Literature
Published findings from the SURPASS and SURMOUNT clinical trial programs have increased research interest in dual incretin pathway signaling. Tirzepatide studies have helped expand the literature around how paired GIP and GLP-1 receptor activation may differ from GLP-1-only approaches in metabolic research models.
Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:
- Coskun et al. (2018) — Mol Metab
- Willard et al. (2020) — JCI Insight
- Rosenstock et al. (2021) — Lancet
- Jastreboff et al. (2022) — N Engl J Med
Storage, Handling & Stability Guidelines
Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.
- Keep ambient-temperature handling time brief to help preserve compound integrity.
- Reseal vials promptly after each withdrawal to reduce moisture exposure.
- Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
- For traceability, label all aliquots with the compound name, concentration, date of reconstitution, and operator initials.
Quality Assurance & Lab Verification
A finalized public Certificate of Analysis is available for this catalog item. Review the public COA for the applicable lot. Lot-specific identifiers, assay values, and methods are maintained in that record and are not repeated in this product dossier.
Shipping
Orders ship within the United States via USPS; international orders are not accepted. Laboratories should follow their validated SOP together with any handling fields published for the represented product or lot; no universal prepared-solution condition is inferred here.
Compound details.
- CAS Number
- 2023788-19-2
- Molecular Weight
- 4813.45 g/mol
- Molecular Formula
- C₂₂₅H₃₄₈N₄₈O₆₈
- Class
- Dual GIP/GLP-1 Receptor Agonist
Research context.
Published data from the SURPASS and SURMOUNT clinical trial programs has generated significant interest in dual incretin signaling. Tirzepatide research has expanded understanding of how combined GIP and GLP-1 receptor activation may differ from GLP-1-only approaches in metabolic studies.
Verification standard.
Certificate information is lot-specific. A finalized public record shows only the methods, fields, and results present for that named lot. A pending certificate state exposes no assay values and must not be interpreted as analytical verification. Review Nexus lab verification.
Analytical record.
- Reported HPLC purity
- 99.55%
- Retention time
- 17.50 min
- Observed mass
- 4813.72 Da
- Batch
- APX-2026-0306-T
The normalized Certificate of Analysis publishes only the lot-specific fields represented in the public record. It is not an originating laboratory report or raw instrument file.
View certificate of analysis - batch APX-2026-0306-T- Sequence
- Not listed
- Model preview
- Unavailable
Molecular model preview is unavailable for this catalog record.
Technical specifications.
- Product Name: Tirzepatide
- Classification: Dual GIP/GLP-1 Receptor Agonist
- Structural Description: 39-amino acid dual GIP/GLP-1 receptor agonist
- CAS Number: 2023788-19-2
- Molecular Weight: 4813.45 g/mol
- Purity: ≥99% (verified by HPLC and Mass Spectrometry)
- Physical Form: Lyophilized (freeze-dried) powder
- Intended Use: In-vitro research use only — not for human consumption
Related research compounds
Comparable catalog records with published variants and certificate status.
- GLP-1 & MetabolicVerified batchSemaglutidePriceFrom $14.99Formats6 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 910463-68-2View product - GLP-1 & MetabolicVerified batchRetatrutidePriceFrom $45.99Formats8 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 2381089-83-2View product - GLP-1 & MetabolicVerified batchcagrilintidePriceFrom $58.99Formats3 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 1415456-99-3View product - GLP-1 & MetabolicVerified batchMazdutidePriceFrom $94.99Formats2 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 2259884-03-0View product - GLP-1 & MetabolicVerified batchSurvodutidePrice$342.99Formats1 size
Compare size options, price, and certificate status before opening the product record.
CAS 2805997-46-8View product
Tirzepatide research FAQ.
What is Tirzepatide used for in research?
Tirzepatide is supplied for controlled in-vitro research workflows in the GLP-1 & Metabolic category. It is not labeled for human or veterinary use.
Does Tirzepatide have a finalized analytical record?
Tirzepatide has a finalized Nexus Lab Verified record that reports 99.55% HPLC area-percent purity for the represented batch. Other fields are shown only where present.
Which Tirzepatide variants are published?
Published Nexus variants include 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 100mg, 120mg.
Does Tirzepatide include a COA?
Yes. The current Nexus record links Tirzepatide to finalized batch APX-2026-0306-T.